H-89 NEW
| Price | $34 | $54 | $116 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-29 |
Product Details
| Product Name: H-89 | CAS No.: 127243-85-0 |
| Purity: 98.06% | Supply Ability: 10g |
| Release date: 2025/05/29 |
Product Introduction
Bioactivity
| Name | H-89 |
| Description | H-89 is a selective and potent protein kinase A inhibitor (IC50: 48 nM), a candidate cardioprotectant, induces spatial learning impairment in rats, and can be used to study myocardial infarction. |
| In vitro | Pretreatment of PC12D cells with H-89 (30 μM) significantly inhibited cAMP-dependent histone IIb phosphorylation activity in cell lysates, but did not affect other protein phosphorylation activities [1]; in rat skin EDL fibers , H-89 (10 μM) only slightly inhibited the force response to depolarization; H-89 (1-2 μM) significantly slowed the re-excitation rate in rat skin EDL fibers, most likely because of its Deleteriously affects the T system potential; H-89 (10-100 μM) also inhibits the net uptake of Ca2+ by SR. [2] |
| In vivo | b>METHODS: H-89 (0.05, 0.1, 0.2 mg/100 g, intraperitoneal injection) was used 30 minutes before the infusion of pentylene tetrazolium (PTZ) in mice to study the effect of H-89 on Bucladesine-induced epileptic activity in PTZ-treated mice. RESULTS: H-89 (0.2 mg/100 g) significantly increased the seizure latency and threshold of PTZ-treated animals; H-89 (0.05, 0.2 mg/100 g) blocked the epileptogenic activity of Bucladesine and significantly increased the seizure latency and seizure threshold. [3] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (134.42 mM), Sonication is recommended. |
| Keywords | protein kinase A | PKA |
| Inhibitors Related | Daphnetin | Capivasertib | GSK180736A | Ellagic acid | Acefylline | Ro-3306 | Metadoxine | Staurosporine | 8-Bromo-cAMP sodium salt | Bucladesine sodium | Fasudil hydrochloride | JAK1/2/3 Inhibitor 1 |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $33.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-05-22 | |
| $0.00/5mg |
VIP1Y
|
Guangzhou Tosun Pharmaceutical Ltd
|
2025-01-23 | |
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-04-27 | |
| $34.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-05-29 | |
| $1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY